[Pubmed] One-year follow up of disease burden and medication changes in patients with myasthenia gravis: from the MG Pat
Posté : 08 juin 2022 12:00
Muscle Nerve. 2022 Jun 8. doi: 10.1002/mus.27659. Online ahead of print.
ABSTRACT
INTRODUCTION/AIMS: We studied the progression of myasthenia gravis (MG) disease burden and medication adjustment among MG Patient Registry participants.
METHODS: Participants diagnosed with MG (aged>=18 years), registered between 7/1/2013-7/31/2018, and completing both 6- and 12-month follow-up surveys were included. Participants were grouped into high- (MG-ADL>=6) and low- (MG-ADL 20%) at 6 months significantly increased likelihood of achieving MSE at 12 months (p = 0.0004).
DISCUSSION: In both groups, but more so in the high-burden group, patients infrequently achieved MSE after 1 year of MG treatment. Baseline low disease burden, improvement at 6 months and no pyridostigmine use were associated with a higher likelihood of MSE at 12 months. This article is protected by copyright. All rights reserved.
PMID:35673964 | DOI:10.1002/mus.27659
Source: https://pubmed.ncbi.nlm.nih.gov/3567396 ... 4&v=2.17.6